Working... Menu

Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma (BPV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02237261
Recruitment Status : Active, not recruiting
First Posted : September 11, 2014
Last Update Posted : May 15, 2018
German Cancer Research Center
Janssen-Cilag International NV
Mundipharma Research GmbH & Co KG
inVentiv Health Clinical
Information provided by (Responsible Party):
Dr. Marc Raab, University Hospital Heidelberg

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : October 2018
  Estimated Study Completion Date : October 2018